Invossa
-
TissueGene, Inc. Announces FDA Acceptance Of Invossa™ As Proprietary Name For TissueGene-C
ROCKVILLE, Md., June 24, 2015 /PRNewswire/ — TissueGene, Inc. today reported that the U.S. Food and Drug Administration (FDA) accepted the proposed…
Read More » -
Extremities
TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement with the Food and Drug Administration (FDA) for its Phase 3 Clinical Trial of Invossa™ for Patients Suffering from Osteoarthritis of the Knee
ROCKVILLE, Md., May 15, 2015 /PRNewswire/ — TissueGene, Inc. announced today that it has reached an agreement with the U.S. Food…
Read More »